Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has earned an average rating of “Moderate Buy” from the twelve analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $20.20.

Several research firms have weighed in on BCYC. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Monday, December 22nd. Truist Financial began coverage on shares of Bicycle Therapeutics in a report on Monday, November 24th. They issued a “hold” rating and a $10.00 target price on the stock. Royal Bank Of Canada reiterated a “sector perform” rating and set a $11.00 price target (down previously from $27.00) on shares of Bicycle Therapeutics in a research note on Friday, October 31st. JMP Securities set a $12.00 price objective on Bicycle Therapeutics in a report on Friday, October 31st. Finally, Citigroup restated an “outperform” rating on shares of Bicycle Therapeutics in a report on Friday, October 31st.

Bicycle Therapeutics Stock Down 2.2%

NASDAQ BCYC opened at $5.24 on Friday. Bicycle Therapeutics has a 52 week low of $5.18 and a 52 week high of $13.11. The business has a 50 day moving average price of $6.64 and a 200-day moving average price of $7.15. The company has a market cap of $363.50 million, a price-to-earnings ratio of -1.45 and a beta of 1.63.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, CFO Alethia Young sold 4,334 shares of Bicycle Therapeutics stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.49, for a total transaction of $28,127.66. Following the transaction, the chief financial officer directly owned 87,081 shares of the company’s stock, valued at $565,155.69. The trade was a 4.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin Lee sold 10,989 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $6.46, for a total transaction of $70,988.94. Following the completion of the sale, the chief executive officer owned 618,996 shares of the company’s stock, valued at approximately $3,998,714.16. The trade was a 1.74% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 38,029 shares of company stock worth $251,966. Company insiders own 22.90% of the company’s stock.

Institutional Investors Weigh In On Bicycle Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Westfield Capital Management Co. LP boosted its stake in shares of Bicycle Therapeutics by 2.2% in the 4th quarter. Westfield Capital Management Co. LP now owns 3,016,026 shares of the company’s stock worth $21,353,000 after buying an additional 63,483 shares during the last quarter. Armistice Capital LLC boosted its position in Bicycle Therapeutics by 6.4% in the third quarter. Armistice Capital LLC now owns 2,978,000 shares of the company’s stock worth $23,050,000 after purchasing an additional 178,000 shares during the last quarter. GSK plc bought a new position in Bicycle Therapeutics in the 4th quarter valued at $10,829,000. Long Focus Capital Management LLC increased its position in shares of Bicycle Therapeutics by 7.7% during the 3rd quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock valued at $10,981,000 after purchasing an additional 101,402 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of Bicycle Therapeutics by 64.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,148,402 shares of the company’s stock worth $8,889,000 after purchasing an additional 451,135 shares during the period. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.